Catheter-Directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis

Brief Summary

Official Title: “Catheter-directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis, an Open Randomized, Controlled, Clinical Trial”

Deep vein thrombosis (DVT) is a severe disease, and conventional treatment with low molecular weight heparin (LMWH) and warfarin is associated with some degree of long-term sequelae, i.e. post-thrombotic syndrome (PTS). Catheter-directed thrombolytic (CDT) therapy has been introduced worldwide the last two decades. Reports have suggested a beneficial effect of this costly treatment, but there are no randomized clinical trials documenting its short- and long-term efficacy and safety. This multi-center study will randomize patients with acute iliofemoral vein thrombosis to either conventional treatment or CDT in addition to conventional treatment. Main outcome parameters are patency rates at 6 months and prevalence of PTS at 24 months. The main short-term hypothesis is that CDT of first-time acute DVT will increase patency of the affected segments after 6 months from <50% to >80%. The main long-term hypothesis is that CDT will improve long-term functional outcome, i.e. risk of PTS after 2 years from >25% to <10%.

  • Study Type: Interventional
  • Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
  • Study Primary Completion Date: December 2011

Interventions Used in this Clinical Trial

  • Procedure: catheter-directed venous thrombolysis
    • catheter-directed continuous intravenous infusion of alteplase 0.01mg/kg/h and low-dose heparin. Max dose 20mg/24 h and up to 96 hrs.

Arms, Groups and Cohorts in this Clinical Trial

  • Experimental: I
  • No Intervention: II

Outcome Measures for this Clinical Trial

Primary Measures

  • Patency after 6 months
    • Time Frame: 6 months
  • Post-thrombotic syndrome after 2 years (yrs)
    • Time Frame: 2 years

Secondary Measures

  • Frequency of clinically relevant bleeding complications
    • Time Frame: 1 year
  • Effects on quality of life
    • Time Frame: 2 and 5 years
  • Cost-effectiveness of treatment
    • Time Frame: 2 years
  • Procedural success of CDT
    • Time Frame: 1 week
  • Patency at 2 years
    • Time Frame: 2 years
  • PTS at 6, 12, 36, 48 and 60 months
    • Time Frame: 6, 12, 36, 48 and 60 months
  • Relation between PTS and patency
    • Time Frame: 2 years
  • Prevalence of vein anomalies
    • Time Frame: 6 months
  • Prevalence of underlying thrombophilia
    • Time Frame: 1 year
  • Frequency of recurrent venous thrombotic events (VTE)
    • Time Frame: 0.5, 2 and 5 years
  • Markers of importance for recurrent thrombosis
    • Time Frame: 0.5, 2 and 5 years
  • Markers of importance for successful thrombolysis
    • Time Frame: 2 years

Criteria for Participation in this Clinical Trial

Inclusion Criteria

  • Onset of symptoms <21 days
  • Objectively verified DVT of the femoral or common iliac veins or the combined iliofemoral segment
  • Informed consent

Exclusion Criteria

  • Anticoagulant therapy prior to trial entry >7 days
  • Contraindications to thrombolytic therapy
  • Indications for thrombolytic therapy, i.e. phlegmasia coerulea dolens or vena cava thrombosis
  • Severe anemia, hemoglobin (hgb)<8 g/dl
  • Thrombocytopenia, platelets <80×10^9/l
  • Severe renal failure, creatinine clearance <30ml/min
  • Severe hypertension, systolic (syst) blood pressure (BP)>160 mmHg or diastolic (diast) BP >100 mmHg pregnancy
  • Less than 14 days post-surgery or post-trauma
  • History of subarachnoidal or intracerebral bleeding
  • Disease with life expectancy <24 months
  • Drug abuse or mental disease that may interfere with treatment and follow-up
  • Former ipsilateral proximal DVT
  • Chemotherapy or advanced malignant disease

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 75 Years

Are Healthy Volunteers Accepted for this Clinical Trial: No

Clinical Trial Investigator Information

  • Lead Sponsor
    • Ullevaal University Hospital
  • Collaborator
    • University Hospital, Aker
  • Overall Official(s)
    • Per Morten Sandset, MD, Study Director, Ullevaal University Hospital

References

Enden T, Klow NE, Sandset PM. [Catheter-directed thrombolysis in acute deep venous thrombosis] Tidsskr Nor Laegeforen. 2006 Jun 22;126(13):1765. Norwegian. No abstract available.

Enden T, Sandvik L, Klow NE, Hafsahl G, Holme PA, Holmen LO, Ghanima W, Njaastad AM, Sandbaek G, Slagsvold CE, Sandset PM. Catheter-directed Venous Thrombolysis in acute iliofemoral vein thrombosis–the CaVenT study: rationale and design of a multicenter, randomized, controlled, clinical trial (NCT00251771). Am Heart J. 2007 Nov;154(5):808-14. Epub 2007 Sep 6.

Enden T, Garratt AM, Kløw NE, Sandset PM. Assessing burden of illness following acute deep vein thrombosis: data quality, reliability and validity of the Norwegian version of VEINES-QOL/Sym, a disease-specific questionnaire. Scand J Caring Sci. 2008 Nov 12; [Epub ahead of print]

Citations Reporting on Results

Enden T, Kløw NE, Sandvik L, Slagsvold CE, Ghanima W, Hafsahl G, Holme PA, Holmen LO, Njaastad AM, Sandbaek G, Sandset PM; CaVenT study group. Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency. J Thromb Haemost. 2009 Aug;7(8):1268-75. Epub 2009 Apr 30.

Source

Clinical Trials content is provided directly by the US National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of information about a specific clinical trial contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00251771